Cocrystal Pharma (NASDAQ: COCP) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its oral antiviral candidate, CDI-988, marking a significant regulatory milestone that could accelerate the drug’s development.
The designation applies to CDI-988’s potential use in both the treatment and prevention of norovirus infections, positioning the program for a more streamlined path through clinical and regulatory processes.
COCP Stock Surges on Regulatory Boost
Investor response was immediate. Shares of Cocrystal Pharma (NASDAQ: COCP) jumped 43% in early Thursday trading to $1.4559, as trading volume spiked to more than 115 million shares, far exceeding the average daily volume of roughly 62,754, according to Yahoo Finance.
The rally adds to a broader upward trend, with the stock now up 65.30% year-to-date. Despite these gains, shares remain about 40% below their 52-week high of $2.67, reached on September 12, 2025.
Why Fast Track Status Matters
The FDA’s Fast Track program is designed to expedite the development of therapies targeting serious conditions with unmet medical needs. For Cocrystal Pharma, the designation brings several strategic advantages.
It enables more frequent engagement with the FDA, allowing the company to address potential issues earlier in the development cycle. Additionally, it permits rolling submission of a New Drug Application (NDA), meaning completed sections can be reviewed without waiting for the full application.
Furthermore, CDI-988 may qualify for Priority Review, which could further shorten the approval timeline.
CDI-988 and Ongoing Clinical Study
While regulatory support is a key tailwind, clinical validation remains essential. CDI-988 is designed to inhibit enzymes critical to norovirus replication, targeting a conserved region shared across multiple virus families.
A Phase 1b study is currently underway at Emory University School of Medicine to evaluate both preventive and therapeutic effects. The randomized, double-blind, placebo-controlled trial will enroll up to 40 healthy adults and assess the drug’s ability to reduce symptoms associated with norovirus infection.
Company Perspective and Market Need
Against this backdrop, company leadership has emphasized the broader significance of the milestone. President and Co-CEO Sam Lee described the Fast Track designation as an important step forward, noting that early data suggest CDI-988 could function as both a preventive and treatment option.
He also highlighted the company’s structure-based drug discovery platform, optimized for developing antivirals targeting multiple viruses.
The need for such treatments is substantial. Norovirus causes an estimated 685 million cases annually worldwide, resulting in an economic burden of roughly $60 billion. In the United States alone, the virus accounts for about 21 million infections each year. These cases lead to approximately 109,000 hospitalizations and 900 deaths.
Taken together, the FDA’s decision strengthens CDI-988’s development trajectory. Although the drug remains in early-stage trials, Fast Track designation provides regulatory momentum that could help accelerate its path toward potential approval.
